Skip to main content

Table 1 Characteristics of included studies and evaluated sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials

From: Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

First Author, year Country Study design Patients (n) Cardiovascular disease (%) CANVAS DECLARE-TIMI 58 EMPA-REG OUTCOME VERTIS-CV
Birkeland, 2018 [23] Germany, the Netherlands, Norway, Sweden RCS 803,836 34
Canivell, 2019 [24] Spain RCS 373,185 23
Nicolucci, 2019 [25] Italy RCS 342,205
Shao, 2019 [26] Taiwan RCS 11,650 27
Wittbrodt, 2019 [27] the United States of America RCS 172,643 64
  1. RCS retrospective cohort study; – not reported